The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Approximately five kg tumor was removed in the eight-hour long complicated surgery
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
The aim is to create an awareness programme that will drive diabetic patients to get their eyes tested regularly
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
_1_256_384.png)
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
The company plans to launch its exclusive e-pharmacy and telemedicine services in India by December 2021
Subscribe To Our Newsletter & Stay Updated
